UPM Raflatac has designed various pharmaceutical labeling products to support compliance with the European Union’s (EU) Falsified Medicines Directive on packaging for prescription drugs and high-risk over-the-counter medicines.
According to the company, few solutions provide the same ease of adoption for meeting the February 2019 deadline.
The Falsified Medicines Directive has made two demands on pharmaceutical product packaging.
Packs have to carry a unique serial number to identify and authenticate individual products, and they need to be sealed in a tamper-evident way which visibly exposes attempts to open them.
UPM's RP62 EU is available with a range of clear label films, while RP62 EUL variant allows missing label detection by luminescent detector.
Pharmaclear PP Seal is a destructible label face that visibly stretches on removal. It doubles up on the tamper-evident functionality of the adhesive for an even higher level of security and avoids misappropriation of the label onto counterfeit products.
UPM Raflatac EMEIA pharma labeling solutions manager Markku Pietarinen said: "UPM Raflatac actively engages with the pharma industry and anticipates legislative change, focusing our materials development precisely for market needs.
"For many pharmaceutical product lines, our PSA label solution is the preferred option. It comes down to the combination of effective tamper-evidence and simplicity of implementation."
Image: UPM Raflatac has designed a range of pharmaceutical labelling products. Photo: courtesy of UPM Raflatac.
